Development of a novel ovarian cancer molecular target therapy against cancer related transcriptional factor, NAC-1
| Project/Area Number |
24592518
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 卵巣癌 / 分子標的治療 / がん遺伝子 / 遺伝子増幅 / 国際情報交換 / 分子標的薬 / 低分子化合物 / 癌遺伝子 |
|---|
| Outline of Final Research Achievements |
Ovarian cancer remains the most lethal gynecologic malignancy, largely due to the lack of effective chemotherapeutic agents in the setting of platinum resistant disease. Chemotherapeutic agents targeting critical molecular pathways hold promise for improving survival in these patients. Understanding the critical molecular pathways is central to the development of such agents. With digital karyotyping, we discovered a new amplified oncogene, NAC-1. Repression of NAC-1 induced apoptosis of ovarian cancer cells.NAC-1 dimerization is integral to its function. Based on the structural analysis of the NAC-1 BTB domain, we screened candidate inhibitors of NAC-1 dimer formation.We have begun development on a carcinogenic mouse model of NAC-1 in which inhibitors will be tested prior to being introduced in the clinical setting.
|
Report
(4 results)
Research Products
(26 results)
-
-
-
-
[Journal Article] PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.2013
Author(s)
Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K.
-
Journal Title
Anticancer Res.
Volume: 33
Pages: 113-118
Related Report
Peer Reviewed
-
[Journal Article] Is ATP7B a predictive marker in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy?2013
Author(s)
Katagiri H, Nakayama K, Rahman MT, Rahman M, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki Y, Miyazaki K.
-
Journal Title
Cancer Res.
Volume: 23
Pages: 60-64
Related Report
Peer Reviewed
-
-
[Journal Article] KRAS and MAPK1 gene amplification in type II ovarian carcinomas.2013
Author(s)
Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Sato E, Iida K, Nakayama N, Ishikawa N, Miyazaki K.
-
Journal Title
Int J Mol Sci.
Volume: 14
Pages: 13748-13762
Related Report
Peer Reviewed
-
[Journal Article] ESR1 gene amplification in endometrial carcinomas: A clinicopathological analysis.2013
Author(s)
Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Nakayama N, Ishikawa N, Miyazaki K.
-
Journal Title
Anticancer Res.
Volume: 33
Pages: 3775-3781
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
